Hitomi Hosoya1,2, Surbhi Sidana3,4. 1. Division of Hematology, Department of Medicine, Stanford University, Stanford, CA, USA. 2. Stanford Cancer Institute, Stanford, CA, USA. 3. Stanford Cancer Institute, Stanford, CA, USA. Surbhi.sidana@stanford.edu. 4. Division of Blood and Marrow Transplantation and Cellular Therapy, Department of Medicine, Stanford University, 300 Pasteur Drive, Room H0101c, Stanford, CA, USA. Surbhi.sidana@stanford.edu.
Abstract
PURPOSE OF REVIEW: The field of multiple myeloma treatment has entered a new era with antibody-based approaches in clinical practice. In this review, we focus on the clinical approaches of utilizing antibody-based modality, specifically monoclonal antibodies, antibody-drug conjugates, and bispecific T-cell antibodies in the treatment of multiple myeloma. RECENT FINDINGS: Three monoclonal antibodies (daratumumab, isatuximab, elotuzumab) and one anti-BCMA (B-cell maturation antigen) antibody-drug conjugate (belantamab mafodotin) have been approved by the FDA in the last 5 years for the treatment of multiple myeloma. There are many ongoing clinical trials using novel targets and constructs, including bispecific antibodies against BCMA, GPRC5D, and FCRH5. In addition to exploring efficacy, there are ongoing efforts to overcome the resistance to therapy. Antibody-based therapy has improved the outcomes of patients with multiple myeloma and has been incorporated in the standard of care. We expect to see novel targets and constructs that can achieve a deeper and more durable response while minimizing toxicity, as well as better strategies for toxicity management for existing agents. We also expect that antibody-based strategies will be used in earlier lines of therapy in the future.
PURPOSE OF REVIEW: The field of multiple myeloma treatment has entered a new era with antibody-based approaches in clinical practice. In this review, we focus on the clinical approaches of utilizing antibody-based modality, specifically monoclonal antibodies, antibody-drug conjugates, and bispecific T-cell antibodies in the treatment of multiple myeloma. RECENT FINDINGS: Three monoclonal antibodies (daratumumab, isatuximab, elotuzumab) and one anti-BCMA (B-cell maturation antigen) antibody-drug conjugate (belantamab mafodotin) have been approved by the FDA in the last 5 years for the treatment of multiple myeloma. There are many ongoing clinical trials using novel targets and constructs, including bispecific antibodies against BCMA, GPRC5D, and FCRH5. In addition to exploring efficacy, there are ongoing efforts to overcome the resistance to therapy. Antibody-based therapy has improved the outcomes of patients with multiple myeloma and has been incorporated in the standard of care. We expect to see novel targets and constructs that can achieve a deeper and more durable response while minimizing toxicity, as well as better strategies for toxicity management for existing agents. We also expect that antibody-based strategies will be used in earlier lines of therapy in the future.
Authors: Peter M Voorhees; Jonathan L Kaufman; Jacob Laubach; Douglas W Sborov; Brandi Reeves; Cesar Rodriguez; Ajai Chari; Rebecca Silbermann; Luciano J Costa; Larry D Anderson; Nitya Nathwani; Nina Shah; Yvonne A Efebera; Sarah A Holstein; Caitlin Costello; Andrzej Jakubowiak; Tanya M Wildes; Robert Z Orlowski; Kenneth H Shain; Andrew J Cowan; Sean Murphy; Yana Lutska; Huiling Pei; Jon Ukropec; Jessica Vermeulen; Carla de Boer; Daniela Hoehn; Thomas S Lin; Paul G Richardson Journal: Blood Date: 2020-08-20 Impact factor: 22.113
Authors: Sagar Lonial; Meletios Dimopoulos; Antonio Palumbo; Darrell White; Sebastian Grosicki; Ivan Spicka; Adam Walter-Croneck; Philippe Moreau; Maria-Victoria Mateos; Hila Magen; Andrew Belch; Donna Reece; Meral Beksac; Andrew Spencer; Heather Oakervee; Robert Z Orlowski; Masafumi Taniwaki; Christoph Röllig; Hermann Einsele; Ka Lung Wu; Anil Singhal; Jesus San-Miguel; Morio Matsumoto; Jessica Katz; Eric Bleickardt; Valerie Poulart; Kenneth C Anderson; Paul Richardson Journal: N Engl J Med Date: 2015-06-02 Impact factor: 91.245
Authors: Andrzej Jakubowiak; Massimo Offidani; Brigitte Pégourie; Javier De La Rubia; Laurent Garderet; Kamel Laribi; Alberto Bosi; Roberto Marasca; Jacob Laubach; Ann Mohrbacher; Angelo Michele Carella; Anil K Singhal; L Claire Tsao; Mark Lynch; Eric Bleickardt; Ying-Ming Jou; Michael Robbins; Antonio Palumbo Journal: Blood Date: 2016-04-18 Impact factor: 22.113
Authors: Laura Moreno; Cristina Perez; Aintzane Zabaleta; Irene Manrique; Diego Alignani; Daniel Ajona; Laura Blanco; Marta Lasa; Patricia Maiso; Idoia Rodriguez; Sonia Garate; Tomas Jelinek; Victor Segura; Cristina Moreno; Juana Merino; Paula Rodriguez-Otero; Carlos Panizo; Felipe Prosper; Jesus F San-Miguel; Bruno Paiva Journal: Clin Cancer Res Date: 2019-01-28 Impact factor: 12.531
Authors: C Madry; Y Laabi; I Callebaut; J Roussel; A Hatzoglou; M Le Coniat; J P Mornon; R Berger; A Tsapis Journal: Int Immunol Date: 1998-11 Impact factor: 4.823
Authors: Sagar Lonial; Brendan M Weiss; Saad Z Usmani; Seema Singhal; Ajai Chari; Nizar J Bahlis; Andrew Belch; Amrita Krishnan; Robert A Vescio; Maria Victoria Mateos; Amitabha Mazumder; Robert Z Orlowski; Heather J Sutherland; Joan Bladé; Emma C Scott; Albert Oriol; Jesus Berdeja; Mecide Gharibo; Don A Stevens; Richard LeBlanc; Michael Sebag; Natalie Callander; Andrzej Jakubowiak; Darrell White; Javier de la Rubia; Paul G Richardson; Steen Lisby; Huaibao Feng; Clarissa M Uhlar; Imran Khan; Tahamtan Ahmadi; Peter M Voorhees Journal: Lancet Date: 2016-01-07 Impact factor: 79.321
Authors: Max S Topp; Johannes Duell; Gerhard Zugmaier; Michel Attal; Philippe Moreau; Christian Langer; Jan Krönke; Thierry Facon; Alexey V Salnikov; Robin Lesley; Karl Beutner; James Kalabus; Erik Rasmussen; Kathrin Riemann; Alex C Minella; Gerd Munzert; Hermann Einsele Journal: J Clin Oncol Date: 2020-01-02 Impact factor: 44.544